Document is current
Any future updates will be listed below
-
Authors
Castillo, Gabriel
Beaty, William
Delau, Olivia
Sultan, Keith
Lukin, Dana
Faye, Adam S.
Friedman, Sonia
Axelrad, Jordan
-
Funding
Funding for this research was provided by:
New York Crohn's and Colitis Organization
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK124570)
- License Information
-
More Information
Article History
Received: 7 September 2025
Accepted: 29 December 2025
First Online: 8 January 2026
Declarations
:
: Jordan Axelrad: Research grants from BioFire Diagnostics, Genentech, Johnson & Johnson, and Takeda. Consultancy fees from AbbVie, Abviax, Adiso, Amgen, bioMérieux, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius, Johnson & Johnson, Merck, Pfizer, Sanofi, Takeda, Vedanta. Dana Lukin: Consultancy fees from Abbvie, Altrubio, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Palatin Technologies, Pfizer, Prime Therapeutics, Prometheus Laboratories, PSI, Takeda, and Vedanta; has received speaker fees from Abbvie and Johnson & Johnson; and has received research grants from Abbvie, Boehringer Ingelheim, Johnson & Johnson, and Takeda. Adam Faye: Consultancy fees from Eli Lilly and BMS; and research grants from AbbVie and Takeda.
: IRB approval was obtained at each individual institution. All subjects signed informed consent prior to enrollment.
